Seyedkazemi Setareh's Form 4 filing
Adverum Biotechnologies, Inc. (ADVM) · filed Sep 18, 2023
- Accession no.
- 0001209191-23-049815
- Filed
- Sep 18, 2023
- Trade date
- Sep 15, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $9.43K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Seyedkazemi SetarehCIK 0001903088 | Officer (Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2023 | Common Stock | SSaleDisposed | −6,071 | $1.52 | −$9,227.92 | 47,804 | Direct | |
| Sep 15, 2023 | Common Stock | SSaleDisposed | −130 | $1.55 | −$201.5 | 47,674 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
In Reporting Person's Form 4 filed on September 16, 2022, a portion of the footnote 1 disclosure reflected that "(a) 1/3 of the shares met a performance condition on September 14, 2022 (of which 50% of these shares vested immediately and 50% of these shares will vest in six months)." The second 50% of the shares actually vested on the one-year anniversary of September 14, 2022. All other information contained in the footnote is correct.